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Abstract
Chemokines and chemokine receptors have been implicated in the selective migration of leukocyte subsets to periodontal
tissues, which consequently influences the disease outcome. Among these chemoattractants, the chemokines CCL3, CCL4
and CCL5 and its receptors, CCR1 and CCR5, have been associated with increased disease severity in mice and humans.
Therefore, in this study we investigated the modulation of experimental periodontitis outcome by the treatment with a
specific antagonist of CCR1 and 5 receptors, called met-RANTES. C57Bl/6 mice was orally infected with Aggregatibacter
actinomycetemcomitans and treated with 0.05, 0.1, 0.5, 1.5 and 5 mg doses of met-RANTES on alternate days, and evaluated
by morphometric, cellular, enzymatic and molecular methods. At 0.5 mg up to 5 mg doses, a strong reduction in the
alveolar bone loss and inflammatory cell migration were observed. Interestingly, 5 mg dose treatment resulted in the
maximum inhibition of inflammatory cell migration, but resulted in a similar inhibition of bone loss when compared with
the lower doses, and also resulted in increased bacterial load and CRP response. When 0.5 and 5 mg therapy regimens were
compared it was observed that both therapeutic protocols were able to downregulate the levels of pro-inflammatory, Th1-
type and osteoclastogenic cytokines, and CD3+ and F4/80+ cells migration to periodontal tissues, but the high dose
modulates host response in a more pronounced and unspecific and excessive way, interfering also with the production of
antimicrobial mediators such as MPO, iNOS and IgG, and with GR1+ and CD19+ cells migration. Our results demonstrate a
thin line between beneficial immunoregulation and impaired host defense during experimental periodontitis, and the
determination of the exact equilibrium point is mandatory for the improvement of immune-targeted therapy of
periodontitis.
Citation: Repeke CE, Ferreira SB Jr, Vieira AE, Silveira EM, Avila-Campos MJ, et al. (2011) Dose-Response Met-RANTES Treatment of Experimental Periodontitis:A
Narrow Edge between the Disease Severity Attenuation and Infection Control. PLoS ONE 6(7): e22526. doi:10.1371/journal.pone.0022526
Editor: Paul Proost, University of Leuven, Rega Institute, Belgium
Received April 7, 2011; Accepted June 23, 2011; Published July 20, 2011
Copyright:  2011 Repeke et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from Fundac ¸a ˜o de Amparo a ` Pesquisa do Estado de Sa ˜o Paulo - FAPESP (06/00534-1). The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: garletgp@usp.br
Introduction
The chronic immune response raised against periodontopatho-
gens in periodontal environment result in the unremitting release
of inflammatory mediators, which trigger soft and mineralized
tissues destruction that typify periodontitis (PD) [1,2]. Among
inflammatory mediators present in PD development, chemokines
are thought to play active roles in the development of host
inflammatory immune reaction, which consequently can directly
impact PD outcome from both tissue destruction and infection
control viewpoints [3,4].
Chemokines are small (8 to 14 Kd) proteins of cytokine family
that coordinate the selective recruitment and function of specific
leukocytes subsets at site of inflammation [5,6]. Regarding PD,
several chemokines have been found in inflamed periodontal tissues
and implicated in disease pathogenesis [4,7,8,9]. In fact, recent
studies suggest that complex chemokine-chemokine receptors
networks operate in periodontal tissues, such as the involvement
ofthechemokinesCCL3,CCL4andCCL5inCCR1+ and CCR5+
cells migration and PD progression [10]. Therefore, the homolo-
gous chemokines CCL3, CCL4 and CCL5 share the specificity for
binding the chemokines receptors CCR1 and CCR5, being
primarily associated with chemoattraction of monocytic lineage
(monocytes/macrophages and dendritic cells) through the binding
to CCR1, while CCR5 also mediates the migration of lymphocytes
polarizedintoTh1 phenotype[5,6,11]. Indeed,chemokine receptor
CCR5 mediates chemoattraction of pro-osteoclastic and osteoclas-
togenic leukocyte subsets throughout experimental PD [12],
reinforcing the role of chemokine system in PD pathogenesis.
Therefore,whileTh1-polarizedlymphocytesandmacrophagescells
are characteristic sources of bone resorptive and inflammatory
cytokines, cells of the monocytic lineage are potentially prone to
develop an osteoclastic phenotype, which may directly impact the
bone resorption activity [10,13,14,15].
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inflammatory diseases, including bone diseases such as rheumatoid
arthritis, they became interesting targets for therapeutic interven-
tion [11,16]. While classic anti-inflammatory drugs impair the
mobilization of leukocyte subsets in a non-selective way, the
development of chemokine/chemokine receptors inhibitors allows
a targeted intervention with potential higher benefits and lower
side effects [11,17]. In fact, while some leukocyte subsets are
potentially destructive during chronic inflammation, certain
subsets are fundamental in the control of infection processes and
in the tissue healing and repair [17,18]. Therefore, the search for
anti-inflammatory and immunomodulatory for intervention in
periodontal diseases ideally must consider both host defense and
tissue destruction viewpoints.
Previous studies demonstrate that the absence of the chemokine
receptors CCR1 and CCR5 result in an attenuated PD phenotype
in mice [10,19], suggesting a potential for therapeutic intervention.
Also, preliminary data demonstrate that the simultaneous
blockade of such receptors with a specific antagonist, called met-
RANTES, result in a higher effectiveness in the inhibition of
inflammatory cell influx and alveolar bone loss [10]. Met-
RANTES is the resultant of the recombinant CCL5 (previously
called RANTES) modification by the extension of the product
with a single methionine residue, which does not compromise the
binding to the cognate receptors but impair the subsequent
signaling and cellular response [20]. In this way, Met-RANTES is
effective in the attenuation of several inflammatory diseases
including rheumatoid arthritis, which share with PD characteris-
tics as the chronic nature of inflammatory response and the bone
resorptive activity [11,20,21,22,23,24,25].
However, while preliminary data suggests a potential applica-
tion of Met-RANTES as a therapeutic strategy in order to control
PD [10], the ideal therapeutic protocol from the dose-response
viewpoint, the mechanisms involved in the virtual attenuation of
PD severity, as well the potential side-effects in the control of
periodontal infection remain unknown. In this study, we
investigated effectiveness of met-RANTES treatment in the
control of experimental PD in mice by means of a dose-response
approach, where tissue destruction and infection markers were
monitored and the possible mechanisms by which met-RANTES
modulates disease outcome were investigated by cellular, enzy-
matic and molecular methods.
Materials and Methods
Experimental groups
Experimental groups comprised 8-week-old male C57BL/6
wildtype (WT) mice, bred and maintained during the experimental
period in the animal facilities of School of Dentistry of Bauru, Sa ˜o
Paulo University - FOB/USP. Throughout the period of the study
the mice were fed with sterile standard solid mice chow (Nuvital,
Curitiba, PR, Brazil) and sterile water. Experimental groups
comprised 12 mice (5 for both flow cytometry and alveolar bone
loss analysis, 3 for RealTimePCR and 4 for ELISA) as described
previously [10,26]. Data from one experiment representative of
two is depicted in the graphs and described in the results section.
The experimental protocol was approved by the Institutional
Committee for Animal Care and Use of the School of Dentistry of
Bauru, Sa ˜o Paulo University, protocols #015/2007 & #016/
2007.
Periodontal infection and Met-RANTES treatment
Bacterial culture and periodontal infection were performed as
described previously [10,26]. In brief, the animals received an oral
delivery of 1610
9 colony-forming units (CFU) of a diluted culture
of A. actinomycetemcomitans JP2 (grown anaerobically in supplement-
ed agar medium, TSBV), in 100 ml of phosphate-buffered saline
(PBS) with 2% of carboxymethylcellulose, placed in the oral cavity
of mice with a micropipette. After 48 and 96 h, this procedure was
repeated. The treatment with met-RANTES (Serono Pharmaceu-
tical Institute of Research, Switzerland) was performed as pre-
viously described [10,27,28], consisting in an intraperitoneal
injection of 0.05, 0.1, 0.5, 1.5 and 5 mg/kg of met-RANTES
diluted in PBS, on alternate days, simultaneously initiated with the
induction of PD protocol until day 30 post-infection, when the
samples were collected. The control groups consisted of non-
infected mice, treated or not with met-RANTES and infected mice
treated or not with vehicle (PBS).
Quantification of alveolar bone loss
Evaluation of the extent of alveolar bone loss was performed as
described previously [10,26]. The maxillae were hemisected,
exposed overnight in 3% hydrogen peroxide and defleshed
mechanically. The palatal faces of the molars were photographed
at 206 magnification using a dissecting microscope (Leica,
Wetzlar, Germany), with the occlusal face of the molars positioned
perpendicularly to the base. The images were digitized and
analyzed using ImageTool 2?0 software (University of Texas
Health Science Center, San Antonio, TX, USA). Quantitative
analysis was used for the measurement of the area between the
cement–enamel junction (CEJ) and the alveolar bone crest (ABC)
in the three posterior teeth, in mm
2. At day 30 post-infection, five
animals were analyzed, and for each animal the alveolar bone loss
was defined as the average of CEJ–ABC between the right and the
left arch; data are presented from one experiment that is
representative of two.
Isolation of inflammatory cells from periodontal tissues
and flow cytometric analysis
The isolation and characterization of leukocytes present in the
lesion site were performed as described previously [10,26]. The
whole buccal and palatal periodontal tissues of upper molars were
collected, weighed and incubated for 1 h at 37uC, dermal side
down, in RPMI-1640, supplemented with NaHCO3, penicillin/
streptomycin/gentamycin and 0.28 Wunsch units/ml of liberase
blendzyme CI (Roche–F. Hoffmann-La Roche Ltd, Basel,
Switzerland). The tissues of five mice were processed in the
presence of 0?05% DNase (Sigma- Aldrich, Steinhein, Germany)
using Medimachine (BD Biosciences PharMingen, San Diego,
CA, USA), according to the manufacturer’s instructions. After
processing, cell viability was assessed by Trypan blue exclusion,
and the cell count was performed in a Neubauer chamber. Flow
Cytometry analysis of leukocyte surface markers and intracellular
cytokines was then performed in fixed and permeabilized cells
with Cytofix/Cytoperm (BD Biosciences), according to the
manufacturer’s instructions. The cells were labeled (4uC/
20 min) with the optimal dilution of PE/FITC-conjugated
antibodies against F4/80, CD3, Gr1 and CD19 staining
antibodies, as well as with respective isotype controls (BD
Biosciences PharMingen), and analyzed with a FACS (FACScan
& CellQuest software, BD Biosciences). The absolute and relative
numbers of leukocyte subsets were calculated based on the total
amount of cells determined in the Neubauer chamber count and
the number of stained cells obtained by FACS. Results represent
the number of cells 6 SD in the periodontal tissues of each
mouse, normalized by the tissue weight, for two independent
experiments.
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Measurements of cytokine in homogenized palatal periodontal
tissue were performed by ELISA as previously described (12),
using commercially available kits (R & D Systems, Taufkirchen,
Germany), as follows: IL-1b (sensitivity .3 pg/ml), TNF-a (.3–
4 pg/ml), IL-6 (1.8 pg/ml), IL-10 (.4 pg/ml), IFN-c (.2 pg/ml),
IL-4 (.2pg/ml), IL-17 (1.6 pg/ml) and RANKL (,3.9 pg/ml).
Data from one experiment representative of two is presented in the
results.
Serum C reactive protein (CRP) measurement
The levels of serum CRP were determined using a commercially
available agglutination kit (Labtest Diagno ´stica, Sa ˜o Paulo, Brazil).
In brief, 50 ml of serum samples (diluted 4, 16, 64, 128 and 256
times), 50 ml of 0?9% NaCl and 50 ml of a solution containing
latex beads coated with anti-CRP antibodies were dispensed in 96-
well plates. The plate was agitated with circular movements for
2 min, and the macroscopic evidence of agglutination was
observed. For the semiquantification of CRP levels, the level of
assay sensitivity (.6 mg/l) were multiplied by the titre of CRP of
each sample. One experiment representative of two is presented in
the results.
Periodontal tissue MPO activity
The activity of MPO in periodontal tissue was measured as
described previously [29]. Briefly, periodontal tissues were
homogenized in ice-cold buffer (0?1 MNaCl, 20 mMNaPO4,
15 mN Na EDTA), pH 4?7, and centrifuged at 3000 g for 15 min.
The pellet was then subjected to hypotonic lysis (900 ml of 0?2%
NaCl solution for 30 s followed by addition of an equal volume of
a solution containing 1?6% NaCl and 5% glucose). After further
centrifugation, the pellet was resuspended in 50 mM NaPO4
buffer, pH 5?4, containing 0?5% hexadecyltrimethylammonium
bromide (H-TAB) and rehomogenized. The homogenate was then
frozen and thawed three times and centrifuged again at 10 000 g
for 15 min at 4uC. MPO activity in the resuspended pellet was
assayed by measuring the change in absorbance at 450 nm using
tetramethylbenzidine (1?6 mM) and H2O2 (0?5 mM). A unit of
MPO activity was defined as that converting 1 mmol of hydrogen
peroxide to water in 1 min at 22uC. Based in control samples and
previous experiments the assay limit detection are MPO 25 as
measured at 490 nm DO. One experiment representative of two is
presented in the results.
Serum antibody to A. actinomycetemcomitans
The levels of serum antibody specific to A. actinomycetemcomitans
were measured as described previously [29]. Briefly, 96-well
microtitre plates (Corning Incorporated, Corning, NY, USA) were
coated with formalin-fixed whole bacterial cells in 0?1 M sodium
carbonate buffer, incubated at room temperature for 4 h, washed
three times with PBS (0?05% Tween 20) and then blocked with
PBS containing 5% bovine serum albumin (BSA) for 30 min.
Serial serum dilutions were added, incubated at room temperature
for 2 h and, after washing the wells three times, 100 ml of
peroxidaseconjugated anti-mouse IgG (Zymed; Invitrogen Life
Technologies, Carlsbad, CA, USA) were added as a detection
antibody. After washing three times, 100 ml of substrate buffer (o-
phenylenediamine dihydrochloride) was added and incubated for
45 min. The enzymatic reaction was stopped by adding 50 ml of 3
N HCl and the absorbances were measured at 492 nm with a
microtitre plate reader (EMAX; Molecular Devices Corporation,
Sunnyvale, CA, USA). Non-infected mice serum was used as a
control for non-specific binding. The IgG levels are expressed as
the antibody serum titre; based in control samples and previous
experiments the assay limit detection for Aa-specific IgG is 0.35 as
measured at 490 nm DO. One experiment representative of two is
presented in the results.
Real-time PCR reactions
Real-time PCR was used to analyze the levels of Aa DNA and
iNOS mRNA in periodontal tissues. The extraction of total RNA
(performed with Trizol reagent, Invitrogen, Rockville, MD, USA)
or DNA (performed with DNA Purification System, Promega
Biosciences Inc., San Luis Obispo, CA, USA) from periodontal
tissues were accomplished as described previously [29]. Both
procedures were performed from a sample comprising the upper
molars with their alveolar bone, and the whole surrounding buccal
and palatal periodontal tissues, which was frozen in liquid
nitrogen, mechanically fragmented and homogenized in sterile
Milli-Q water with Ultra Turrax (IKA, Germany), and subse-
quently submitted to DNA or RNA extraction. Real-time PCR
quantitative mRNA or DNA analyses were performed in
MiniOpticon system (BioRad, Hercules, CA, USA) using the
SybrGreen system (Applied Biosystems, Warrington, UK). Sybr-
Green PCR MasterMix (Applied Biosystems), 100 nM specific
primers (designed with the software Primer Express 3.0 from
Aplied Biosystems, Foster City, CA, USA; and subsequently
synthesized by Invitrogen; iNOS - sense: CGTCATTTCTGT-
CCGTCTCT; anti-sense: TTGCTGGCTGATGGCTGGCG;
and A. actinomycetemcomitans JP2 - Sense: ATGCCAACTTGAC-
GTTAAAT; anti-sense: AAACCCATCTCTGAGTTCTTCTT-
C; b-actin - sense: ATGTTTGAGACCTTCAACA; anti-sense:
CACGTCAGACTTCATGATGG) and 2.5 ng of cDNA or 5 ng
of DNA in each reaction [10]. The standard PCR conditions are
were 95uC (10 min), followed by 40 cycles of 94uC (1 min), 56–
65uC (1 min) and 72uC (2 min), and by the standard denaturation
curve. For RNA analysis, gene expression levels were determined
using the Ct method and normalized by housekeeping gene beta-
action, while for Aa DNA quantification, in the view of the
absence of an internal control (or a standard curve for absolute
quantification), DNA levels were determined using the Ct method
with reference to a positive control of Aa DNA from culture and
then normalized by the tissue weight to avoid technical variances
and interferences in the results. Negative controls without cDNA/
DNA and without reverse transcriptase were also performed; data
are presented from one experiment that is representative of two.
Statistical analysis
Data are presented as means 6 SD, and the statistical
significance between the infected and control groups of WT and
met-RANTES treated mice was analyzed by ANOVA, followed
by Bonferroni post test, or by the unpaired t-test, both performed
with GraphPad Prism 5.0 software (GraphPad Software Inc., San
Diego, CA). Values of P,0.05 were considered statistically
significant.
Results
Dose response analysis of met-RANTES treatment effect
in experimental PD outcome
Our first aim was to determine the dose of met-RANTES which
result in maximum decrease of experimental PD severity
parameters (Fig. 1). When compared to untreated and vehicle-
treated mice, met-RANTES doses of 0.1, 0.5, 1.5 and 5 mg were
found to significantly inhibit both alveolar bone loss and
inflammatory cell influx. When the distinct doses were compared,
the 0.1 mg doses was found to be less effective than 0.5, 1.5 and
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differences were found between these three higher doses.
Regarding inflammatory cell counts, our results demonstrate that
as a general rule the dose increase resulted in a gradual decrease of
inflammatory cell influx into periodontal tissues, except for non-
significant differences between the doses of 0.5 and 1.5, and 1.5
and 5 mg. When the bacterial load was evaluated, our results
demonstrated that only the 5 mg dose interfered in the control of
infection, as revealed by the significant increase in AA DNA levels
in periodontal tissues when compared to untreated, vehicle-treated
and to the other met-RANTES doses groups. During the
experimental period the mice mortality was absent and no
significant change in mice weight among the experimental groups
was verified (data not shown). Our results demonstrate that 10X
dose range resulted in distinct modulation of experimental PD
outcome from the tissue destruction and infectious viewpoints, and
therefore the doses of 0.5 and 5 mg were selected for the
subsequent evaluations.
Phenotypic analysis of leukocytes migration interference
by distinct doses of met-RANTES treatment
In order to determine the mechanisms underlying the
differential response to 0.5 and 5 mg met-RANTES doses, we
initially investigated the interference of the distinct doses in the
migration of F4/80+, CD3+, Gr1+ and CD19+ cells (Fig. 2). The
0.5 mg dose resulted in a significant reduction in the relative
number of F4/80+ and CD3+ cells, while no differences was
observed in the reduction of relative number of Gr1+ and CD19+
cells when compared with non-treated and vehicle-treated mice.
Differently, the 5 mg met-RANTES protocol reduced the relative
% of F4/80+, CD3+, Gr1+ and CD19+ cells in the periodontal
tissues when compared with 0.5 mg of MetRANTES.
The distinct dose-response modulation of cytokine
milieu in periodontal tissues by met-RANTES
In order to determine the mechanisms underlying the
differential response to 0.5 and 5 mg met-RANTES doses, we
next analyzed the levels of several cytokines in periodontal tissues
of mice by ELISA (Fig. 3). Our results demonstrate that, as a
general rule, both 0.5 and 5 mg were able to decrease the
production of proinflammatory cytokines IL-1b, TNF-a and IL-6
in periodontal tissues, but in different degrees, since 5 mg dose
resulted in a higher decrease of TNF-a and IL-6 when compared
to the 0.5 mg dose. Complementarily, our data demonstrate that
only the 5 mg dose resulted in a significant modulation of the anti-
inflammatory cytokine IL-10 when compared to the other
Figure 1. The effect of met-RANTES treatment at different doses in the modulation of alveolar bone loss, inflammatory cell influx
and bacterial load in experimental periodontal disease. C57Bl/6 mice were infected orally with A. actinomycetemcomitans and treated with
met-RANTES at 0.05, 0.1, 0.5, 1.5 and 5 mg doses or (V) veicule, (-) non treated and (C) control non-infected mice and evaluated at 30 day post-
infection for: A) alveolar bone loss quantification, performed through the measurements of cement-enamel junction-alveolar bone crest (CEJ-ABC)
area in the palatal face of maxillary molars; B) total leukocyte counts of inflammatory infiltrate, performed in a Neubauer chamber; and C) A.
actinomycetemcomintans load (AA DNA) in periodontal tissues, quantified by Real-TimePCR, using SybrGreen System and the cycle threshold (Ct)
method; all performed as described in the Material and methods; *p,0.05 versus non-treated mice, unpaired t-test. Different italic low case letters
represent statistically significant differences among the doses in the same experimental group (P,0.05; One-way ANOVA).
doi:10.1371/journal.pone.0022526.g001
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evaluated (Fig. 4), it was observed that IFN-c levels were
significantly reduced by both 0.5 and 5 mg when compared to
controls, but this change was significantly more prominent with
the 5 mg dose. Regarding IL-4 and IL-17A levels, only the 5 mg
dose resulted in a decrease in the level of such cytokines in the
periodontal tissues of AA-infected mice. Finally, we observed that
both 0.5 and 5 mg treatment resulted in decreased levels of
RANKL in periodontal tissues at the same extent, when compared
to the controls.
The distinct dose-response modulation of antimicrobial
response by met-RANTES therapy
In the view of the distinct effect of 0.5 and 5 mg met-RANTES
doses in the bacterial load in periodontal tissues, we next
investigated the levels of antimicrobial factors and the systemic
infection parameter C reactive protein (CRP) (Fig. 5). Our results
demonstrate that the levels of the antimicrobial factor and PMN
marker MPO in periodontal tissues were differentially modulated
by the distinct met-RANTES doses, while 0.5 mg dose resulted in
a slight (but significant) increase of MPO levels, the 5 mg dose
resulted in a lower level of MPO activity in periodontal tissues
than controls. Regarding the levels of iNOS mRNA, our results
demonstrate that iNOS expression in periodontal tissues was
significantly reduced by both 0.5 and 5 mg when compared to
controls, but a major downregulation was verified with the 5 mg
dose. When the levels of serum AA-specific IgG were investigated,
our results demonstrate that only 5 mg met-RANTES dose
resulted in a decrease of antibody levels. Finally, our data
demonstrate that the levels of systemic inflammation marker
CRP were slightly decreased (non-statistically significant) by the
0.5 mg met-RANTES dose, while the 5 mg dose resulted in a
significant increase in serum CRP when compared with the other
experimental groups.
Discussion
PD is characterized by the chronic host response triggered by
periodontopathogens that result in soft and mineralized tissues
destruction [1,2]. Among the host mediators involved in the
generation and maintenance of this exacerbated inflammatory
immune response, chemokines and chemokine receptors have
been implicated in PD development [3,4,30]. The chemokines
receptors CCR5 and CCR1 are supposed to mediate the
chemoattraction of lymphocytes polarized into Th1 phenotype
and monocytes/macrophages into periodontal tissues, which
consequently contributes to disease progression [3,4,8,19]. Pre-
liminary results demonstrate that a specific blocker of CCR5 and
CCR1 chemokine receptors, called met-RANTES, was able to
decrease the experimental PD severity [10]. However the
mechanisms involved in such modulation, the ideal dose of met-
RANTES to achieve the maximum remission of experimental PD,
as well potential side effects concerning the infectious aspects of the
disease remain unknown.
Therefore, we initially performed a dose-response (5 doses with
a 100X range, 0.05 to 5 mg) analysis of experimental PD outcome
following met-RANTES therapy. The alveolar bone loss and
inflammatory cell influx were used as the disease severity
parameters, and the bacterial load in the periodontal tissues was
Figure 2. Phenotypic analysis of leukocytes migration interference by distinct doses of met-RANTES treatment. C57Bl/6 mice were
infected orally with AA, treated with met-RANTES at 0.5 and 5 mg doses or (V) veicule and (-) non treated, sacrificed at day 30 post-infection and
evaluated for relative number of: A) F4/80+; B) CD3+; C) Gr1+; and D) CD19+ cells in periodontal tissues of WT non-treated versus vehicle, 0.5 mg and
5 mg met-RANTES treated mice by flow cytometry, all performed as described in Material and methods. Results demonstrate the relative number of
cells in % when compared with untreated group. Different italic low case letters represent statistically significant differences among the doses in the
same experimental group (P,0.05; One-way ANOVA), statistical analysis performed with raw data before % conversion.
doi:10.1371/journal.pone.0022526.g002
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dose, all the other doses (0.1 up to 5 mg) resulted in a significant
decrease of experimental PD severity. Interestingly, as a general
rule a dose-response effect was identified in the attenuation of
inflammatory cells influx, while a similar inhibition of bone
resorption was achieved with the doses ranging from 0.5 up to
5 mg. The effectiveness of the met-RANTES in the control of
inflammation-associated tissue damage is in agreement with
previous studies [22], but deeper comparisons with other models
are impaired by the relatively low number of previous studies,
performed in quite different experimental models usually investi-
gating one or at most two different met-RANTES doses within a
narrow interval [31,32,33]. Interestingly, the PD treatment with
5 mg of met-RANTES dose impaired the control of periodontal
infection, evidencing to distinct situations, where similar protective
effects from the tissue destruction viewpoint are associated with
distinct (normal and impaired) infectious outcomes. Therefore, in
order to investigate the mechanisms underlying such differential
response, the experimental groups receiving met-RANTES doses
of 0.5 and 5 mg were selected for the further analysis.
The first scenario, represented by the 0.5 mg met-RANTES
protocol, can be interpreted as a clinically desired situation, where
the tissue damage was minimized without interfering with host
defense process. In fact, the 0.5 mg met-RANTES dose was
effective in reducing F4/80 (a monocytic lineage marker) and CD3
cells (CD3 lymphocytes), which present CCR1 and CCR5
receptor in its membranes, and also was observed a reduction in
the tissue levels of pro-inflammatory cytokines IL-1b, TNF-a and
IL-6. These cytokines are classically implicated in the onset and
progression of PD by its role in osteoclastogenic process [2,34,35],
being the reduction in its levels compatible with the attenuation of
the experimental disease severity observed. Accordingly, met-
RANTES therapy target cells from the monocytic lineage,
characteristic sources of IL-1b, TNF-a and IL-6 [33]. Also in
agreement with our findings, met-RANTES treatment also
reduced TNF-a and IL-1b levels in a rat arthritis model [31,33].
In addition, 0.5 mg dose of met-RANTES was able to reduce
CD3+ cells in the periodontal tissues, which potentially include
Th1-polarized lymphocytes, the main source of IFN-c, which can
also justify the downregulation of the IFN-c levels observed. In
spite of some controversies, IFN-c is present at high levels in
periodontal lesions and associated with higher PD severity [29,36].
Th1 cells are also supposed to be a significant source of the major
osteoclastogenic factor RANKL in periodontal environment
[12,37]. Accordingly, met-RANTES therapy also resulted in a
significant downregulation of RANKL levels, which also could
account for a direct effect in the inhibition of bone resorptive
process [38].
Interestingly, the levels of IL-10, IL-4 and IL-17A were not
modulated by the 0.5 mg met-RANTES treatment, suggesting a
specific effect over determined leukocyte subsets. Also, met-
RANTES treatment at 0.5 mg dose does not interfere in the
migration of Gr1 and CD19 positive cells to periodontal tissues,
reinforcing the specificity of the leukocyte subsets targeted by met-
Figure 3. Met-RANTES treatment at different doses modulate pro- and anti- inflammatory cytokine levels in experimental
periodontal disease. C57Bl/6 mice were infected orally with AA, treated with met-RANTES at 0.5 and 5 mg doses or (V) veicule, (-) non treated and
(C) control non-infected mice, sacrificed at day 30 post-infection and evaluated for levels of A) IL-1b; B) TNF-a; C) IL-6 and D) IL-10 cytokines. Different
italic low case letters represent statistically significant differences among the doses in the same experimental group (P,0.05; One-way ANOVA).
doi:10.1371/journal.pone.0022526.g003
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specifically modulate adaptive immunity through the interference
with dendritic cell traffic from peripheral tissues to lymphoid
organs, which involves the receptor CCR5 [39]. It is also
important to consider that even in the total absence of CCR1
and CCR5 function (which is probably not fully achieved in vivo
even with substantially high met-RANTES doses), a remaining
migration of monocytic lineage cell and Th1 lymphocytes is still
expected and possibly mediated by other chemokine receptors,
such as CCR2 and CXCR3, respectively [40]. This redundancy in
the chemokine system possibly account for the residual (but
significant) IFN-c and pro-inflammatory cytokine production
verified in the animal treated with met-RANTES. Interestingly,
when considered from the infectious viewpoint, the 0.5 mg met-
RANTES treatment protocol was found to not interfere in the
control of experimental infection (as evidenced by the similar
bacterial load in periodontal tissues and CRP serum levels),
reinforcing therefore a potential clinical application of met-
RANTES to treat PD.
However, in the second scenario identified, the increase of met-
RANTES dose to 5 mg in spite of an additional reduction in the
inflammatory cell influx, does not result in further inhibition of
bone loss and impair host defense. Concerning the more
pronounced effect of the 5 mg dose in the inhibition of
inflammatory cell influx, this group presented lower levels of
TNF-a, IL-6, IFN-c and IL-17 when compared to the group with
received 0.5 mg of met-RANTES, which could account for the
additional reduction in cell migration observed, not only in the
total amount of inflammatory cells but also in the population of
macrophages and CD3 lymphocytes. However, regarding the
comparable bone loss levels presented by both groups, it is possible
that the similar levels of RANKL in the tissues are responsible for
the equivalent bone resorption degree. Interestingly, the levels of
IL-17A and IL-4, theoretically products of Th17- and Th2-
polarized lymphocytes, were also reduced by the 5 mg met-
RANTES dose. Since Th17 and Th2 helper subsets specifically
migrate using the chemokine receptors CCR6 and CCR4/CCR8
[5,41], not targeted by met-RANTES, our data demonstrate that
the higher dose result in a broader and probably unspecific
modulation of host response, not observed with the 0.5 mg dose.
One possible explanation for such phenomenon is that the high
met-RANTES doses could interfere indirectly in the cell migration
mediated by other receptor than CCR1 and CCR5. In fact, our
data demonstrate a reduction in the number of CD19 and Gr1
positive cells, presumably B cells and neutrophils respectively, cells
which normally do not present CCR1 and CCR5 receptors, by
5 mg dose of met-RANTES. Chemokine receptor blockade by
met-RANTES limits the endothelial cell-leukocyte interaction,
which consequently can limit the migration process even if
mediated by non-blocked receptors [42]. Also, the continuous
administration of a high amount of met-RANTES may result in
physical competition with other chemokines for binding sites in the
Figure 4. Met-RANTES treatment at different doses modulate Th1, Th2, Th17 cytokine and osteclastogenic factor RANKL levels in
experimental periodontitis. C57Bl/6 mice were infected orally with AA, treated with met-RANTES at 0.5 and 5 mg doses or (V) veicule, (-) non
treated and (C) control non-infected mice, sacrificed at day 30 post-infection and evaluated for levels of A) IFN-c, a Th1 cytokine; B) IL-4, a Th2
cytokine; C) IL-17A, a Th17 cytokine and D) the major osteoclastogenic factor RANKL. Different italic low case letters represent statistically significant
differences among the doses in the same experimental group (P,0.05; One-way ANOVA).
doi:10.1371/journal.pone.0022526.g004
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chemokines to the glycosaminoglycan side chain of ECM
proteoglycans generates a chemotactic gradient required for the
directional cell migration [43]. Therefore, the predominance of
met-RANTES distribution over the ECM would impair or limit
the presence of other chemoattractants and consequently result a
broader interference in chemotaxis process. However, the
glycosaminoglycan-binding properties of met-RANTES remain
unknown. An additional hypothesis is that the more pronounced
modulation of cytokine production by the high met-RANTES
doses impact as a cascade the sequential immune response,
modulating differentially the local production of other chemokines
that consequently impact the subsequent response.
The broad and unspecific immunomodulation promoted by the
high met-RANTES doses is also perceptible by the analysis of the
host antimicrobial response. Indeed, our data demonstrate that
MPO and IgG levels were only affected by the 5 mg dose
treatment. MPO and IgG are products of neutrophils and B cells
respectively, cells types supposedly to not be primarily affect by the
interference with CCR1 and CCR5 promoted by met-RANTES
[10]. In accordance with such hypothesis, 5 mg dose of met-
RANTES treatment reduced the number of both Gr1+ and
CD19+ cells in the infected periodontal tissues. In addition, it is
important to mention that the expression of the antimicrobial
enzyme iNOS was also greatly diminished by the 5 mg met-
RANTES dose. Taken together, the reduction in the innate and
adaptive antimicrobial response is possible responsible for the
increase in the bacterial load found in periodontal tissues.
Accordingly, MPO, iNOS and IgG are supposed to contribute
to the killing of periodontal bacteria [26,29,44,45]. Therefore, it is
possible to conclude that an excessive downregulation of host
response by the high met-RANTES doses significantly impair host
response overcoming the protective effect presented by lower
doses. In fact, the significant increase in serum CRP levels
reinforces the compromised host response presented by mice
treated with high met-RANTES doses.
In this setting, an important question refers to nature and
intensity of host response required to assure a proper defense
against the periodontopathogens. Since a series of therapeutic
proposals targets the modulation of host response, the exact
determination of the leukocyte subsets, cytokines and antimicro-
bial factors really involved in the control of periodontal infection is
fundamental to direct future host-targeted therapies. When the
results presented here are compared with a previous study of our
group, were a mice strain selected for minimal inflammatory
response (AIRmin) was evaluated [23], interesting information
arise. AIRmin strain and the C57BL/6 mice treated with 5 mg
met-RANTES dose present similar inflammatory and bone loss
scores, and also similar production of IL-1b and TNF-a [23].
However, AIRmin strain efficiently controls the experimental
periodontal infection, a finding associated with higher IFN-c
production than met-RANTES-treated mice [23]. Also, while
Figure 5. The effect of distinct met-RANTES doses treatment in the control of A. actinomycetemcomitans infection. C57Bl/6 mice were
infected orally with AA, treated with met-RANTES at 0.5 and 5 mg doses or (V) veicule, (-) non treated and (C) control non-infected mice, sacrificed at
day 30 post-infection and evaluated for: A) levels of myeloperoxidase (MPO) in periodontal tissues; B) levels of inducible nitric oxide syntase (iNOS)
expression; C) levels of Aa-specific IgG; and D) levels of C reactive protein (CRP) in serum; all performed as described in Material and methods.
Different italic low case letters represent statistically significant differences among the doses in the same experimental group (P,0.05; One-way
ANOVA).
doi:10.1371/journal.pone.0022526.g005
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RANTES-treated mice, 5 mg met-RANTES treatment resulted in
lower IgG response than observed in AIRmin strain [23]. In
accordance with previous studies [29,45], these results point to
important roles of IFN-c and antibody production in the control of
periodontal infection [2]. Therefore, it is possible to suggest that
immunoregulatory strategies aimed to control PD should not
interfere with these mediators. However, it is important to
consider that a highly complex host-pathogen interaction takes
place in the periodontal environment, and that the exact nature
and intensity of the ‘‘ideal’’ protective host response remain to be
determined. Also in this context, it is important to mention that
while PD and rheumatoid arthritis are often compared in the view
of the similar chronic nature of inflammatory response and the
bone resorptive activity; the theoretical sterile condition of arthritis
versus the infective nature of PD result in more complex scenario
in the case of PD, where an additional factor is added to an
already intricate system.
In summary, our results demonstrate that the therapeutic
efficacy of met-RANTES treatment of experimental PD is dose-
dependent. While low to intermediate doses are effective in
attenuating inflammatory cell migration and bone loss via
downregulation of the local level of pro-inflammatory, Th1-type
and osteoclastogenic cytokines, high doses seem to modulate host
response in a unspecific and excessive way, resulting a more
pronounced modulation of cytokine production and interfering in
the host antimicrobial response. This results points to a potential
role of met-RANTES in the clinical management of PD, but
reinforce the requirement of detailed and careful investigation of
the degree of host response aimed in the view of potential side-
effects associated.
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